Tonix Pharmaceuticals (TNXP) stock plunged after the company carried out a 1-for-100 reverse stock split as it awaits approval for its breakthrough fibromyalgia treatment.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The reverse stock split was intended to increase the per share trading price of TNXP stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq.
TNXP Awaits FDA Decision
However, the 54% decline on Monday, February 3rd, sent shares to just $0.19. Further losses in pre-market trading on Tuesday sent the shares down a further 18% to $0.16, raising the prospect that the company could be delisted before it wins approval on its key drug treatment.
TNXP is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on TNX-102 SL for fibromyalgia management, with a decision date slated for August 15th, 2025.
Tonix submitted a New Drug Application to the FDA in October 2024. If approved, it would be the first new treatment in 15 years for fibromyalgia, a chronic condition that causes widespread pain and tenderness in the body as well as sleep problems.
Tonix also has several other products in development, including TNX-1300 for cocaine intoxication and TNX-1500 for organ transplant rejection. Additionally, the company has secured a Department of Defense contract worth up to $34 million for developing TNX-4200, its broad-spectrum antiviral.
Is TXNP a Good Stock to Buy?
Only one Wall Street analyst has set a 12-month price target for TXNP in the last three months, although this was produced before the reverse stock split.
